Efficacy and Safety of High- vs Low-Dose Sirolimus in Patients with Kaposiform Hemangioendothelioma: A Randomized Clinical Trial

Sirolimus is recommended for the treatment of kaposiform hemangioendothelioma (KHE). However, the optimal sirolimus dose for the treatment of KHE remains unknown. A prospective multicenter study was conducted to evaluate the noninferiority and safety of low-dose versus high-dose sirolimus in patients exhibiting KHE without Kasabach–Merritt phenomenon (KMP). Among the 79 participants included in the study, low-dose sirolimus is noninferior to high-dose sirolimus, suggesting that it may be an effective and safe option for KHE without KMP.